U.S. Remote Patient Monitoring Market Size & Share 2025 - 2034

U.S. Remote Patient Monitoring Market Size

The U.S. remote patient monitoring market (RPM) was valued at USD 9.4 billion in 2024 and is projected to grow from USD 10.2 billion in 2025 to USD 25.2 billion by 2034, expanding at a CAGR of 10.6% according to Global Market Insights. This steady growth is stimulated by various factors such as growing prevalence of chronic diseases one of which is prevalence of diabetes across the U.S., policy and reimbursement support. Major companies in the industry include Abbott Laboratories, Dexcom, Medtronic, Koninklijke Philips, and Boston Scientific.

The U.S. Remote Patient Monitoring Market has seen tremendous growth, increasing from USD 7.2 billion in 2021 to USD 8.6 billion in 2023, due to rising prevalence of chronic conditions such as diabetes, cardiovascular diseases, and hypertension. These conditions necessitate continuous monitoring and timely interventions to prevent complications, hence making RPM solutions indispensable. For example, diabetes is the leading cause of this trend. In the U.S., there were 38.4 million people of all ages who had diabetes in 2023, with 11.6% of the population, including 38.1 million adults aged 18 years or older, accounting for 14.7% of all U.S. adults. This large patient base underlines the urgent need for effective disease management tools. And with a growing number of people suffering from chronic diseases, health systems are increasingly adopting proactive, technology-driven care models.
 

RPM platforms enable the tracking of critical parameters like blood glucose, blood pressure, and heart rate by patients themselves from the comfort of their homes, thereby reducing hospitalization and enhancing outcomes. Therefore, the increasing burden of chronic diseases accelerates the adoption and development of RPM solutions, with the latter turning into a cornerstone for contemporary chronic care management.
 

The remote patient monitoring (RPM) market encompasses medical technologies designed to collect, transmit, and analyze patient health data outside of traditional clinical settings. This includes a wide range of devices that monitor vital signs, chronic conditions, and other health metrics, enabling healthcare providers to track patient status remotely. The market also includes integrated software platforms that facilitate data collection, analysis, and communication between patients and providers. Additionally, it covers compatible monitoring devices developed by manufacturers to work seamlessly with proprietary RPM software solutions, ensuring interoperability and efficient remote care delivery.
 

U.S. Remote Patient Monitoring Market Trends

• The market is standing at the edge of transformation driven by technological innovation, change in care models, and increase in demand for chronic disease management.
   
• There are rapid developments in the fields of AI, IoT, and biosensor technologies that offer continuous and real-time data collection and predictive analytics. These tools will permit clinicians to identify the early signs of deterioration, enable early intervention, and reduce hospital readmissions.
   
• For example, AI-driven algorithms analyze trends in blood pressure, glucose levels, and respiratory rates to predict complications and improve patient outcomes and operational efficiency.
   
• In addition, strategic partnerships between device manufacturers and digital health companies, academic institutions, and providers help not only foster flexible innovative and scalable solutions but also ensure that the products meet regulatory standards laid out in the U.S. Such partnerships provide opportunities for clinical validation and further integration with EHR, telehealth, and pharmacy systems to form one smooth ecosystem around the remote care monitoring market.
   

U.S. Remote Patient Monitoring Market Analysis

Based on product, the U.S. market is divided into cardiac monitoring devices, blood pressure monitors, neurological monitoring devices, multiparameter monitoring devices, blood glucose monitoring devices, fetal and neonatal monitoring devices, sleep monitoring devices, and other monitoring devices. The cardiac monitoring devices segment held a significant market share of 19.6% in 2024.
 

• Growth in this segment is driven mainly by the high prevalence of cardiovascular diseases in the U.S. and the growing requirement for continuous real-time monitoring to enable early diagnosis and timely intervention.
   
• There are significant technological improvements in cardiac RPM devices, including precision and reliability. AI-powered analytics and deep sensor integrations have made tracking of heart rhythms, heart rate variability, and other vital cardiac metrics possible with accuracy.
   
• These innovations are especially important in arrhythmia, atrial fibrillation, and early signs of cardiac distress, thus supporting preventive care and avoiding emergency hospital visits.
   
• The leading U.S. manufacturers are presenting advanced solutions for remote cardiac monitoring. Thus, Medtronic's LINQ II insertable cardiac monitor includes an algorithm called AccuRhythm AI because it is designed to provide more precise arrhythmia detection.
   
• This device provides long-term monitoring for patients with unexplained syncope or suspected arrhythmia, allowing for clinician decision-making based on continuous data. The Abbott Confirm Rx, powered by SharpSense technology, wirelessly sends cardiac data over Bluetooth to a patient’s smartphone, allowing real-time data sharing and increasing patient engagement along with clinical responsiveness.
   
• With value-based care and home-based monitoring on the rise within U.S. healthcare systems, cardiac RPM devices are increasingly becoming critical tools in chronic disease management, post-operative recovery, and elderly care.
   

Based on application, the U.S. remote patient monitoring market is bifurcated into cardiovascular diseases, cancer, diabetes, neurological disorders, infectious diseases respiratory diseases, and other applications. The diabetes segment held a significant market share of 56.4% in 2024 driven by the rise in diabetes prevalence and the increasing need for continuous, real-time disease management.
 

• The CDC estimated that over 38 million Americans have diabetes, and of those, 90-95% have Type 2 diabetes. Though adults over age 45 are most affected by this condition, diagnoses among younger populations are increasing, making accessible and effective monitoring solutions ever more important.
• Management of diabetes involves frequent monitoring of blood glucose, administration of insulin, and other metabolic parameters, hence making RPM devices highly essential for improving patient outcomes by reducing complications. Technological advancement has greatly improved the management of diabetes through RPM.
   
• Modern devices boast of high-accuracy sensors, AI-powered analytics, and cellular connectivity, thus allowing seamless transmission of data and early detection of complications such as hypoglycemia and hyperglycemia.
   
• RPM solutions also support personalized care by analyzing individual health data over time to tailor interventions to each patient’s unique needs. This approach improves adherence and patient satisfaction, particularly for elderly individuals, those with comorbidities, and patients in remote or underserved areas.
   
• As U.S. healthcare systems embrace value-based care and home-based monitoring, blood glucose RPM devices are becoming essential tools in chronic disease management. Their ability to deliver accurate, real-time insights and facilitate proactive care is accelerating adoption across hospitals, specialty clinics, and home care settings. Combined with strong reimbursement support through RPM-specific CPT codes, this segment is poised for sustained growth in the coming years.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the U.S. remote patient monitoring market is bifurcated into home-care settings, long-term care, and other end users. Among these, the home-care settings segment accounts for 69.8% of the total market share.
 

• There has been a significant growth in the adoption of home-based monitoring devices in the market, driven by an increasing preference for decentralized care and aging in place. Thus, it has resulted in empowering patients to take proactive health management while considering reducing the frequency of visits to the hospitals, hence making it align with the country's approach toward value-based care and digital health transformation.
   
• Technology has smoothed out many of the usability and accuracy issues with RPM devices, making them accessible for in-home usage. With modern solutions, there is real-time tracking of vital signs, automated alerts, and easy data sharing with healthcare providers. Many systems integrate with smartphones and digital health platforms for easy tracking of health metrics and data sharing by patients.
   
• COVID-19 accelerated a switch to home-based healthcare solutions in the U.S., with patients looking to minimize their exposure to clinical environments. This has continued into post-pandemic times and further engrained RPM's role in decentralized healthcare delivery. The aging U.S. population, along with a growing preference to age in place, is expanding the segment of home care.
   
• With personalized, real-time insights in care coordination becoming increasingly prioritized, home-based RPM devices are fast cementing their place as cornerstones in modern healthcare delivery throughout U.S. healthcare systems.
   

U.S. Remote Patient Monitoring Market Share

• Top 5 companies such as Abbott Laboratories, Dexcom, Medtronic, Koninklijke Philips, and Boston Scientific dominate the U.S. RPM market with a collective market share of 70% through advanced product portfolios, strong provider partnerships, and continuous innovation. Their offerings span cardiac monitoring, continuous glucose monitoring, multiparameter devices, and integrated digital platforms, enabling real-time data sharing and proactive care management.
   
• Emerging players and niche innovators are gaining traction by introducing AI-powered analytics, wearable biosensors, and smartphone-integrated RPM solutions. These companies focus on user-friendly designs and interoperability, appealing to tech-savvy patients and supporting decentralized care models.
   
• To strengthen market position, top players actively engage in partnerships, acquisitions, and technology collaborations. These strategies accelerate product development, enhance connectivity with EHR and telehealth platforms, and expand RPM capabilities for chronic disease management and hospital-at-home programs.
   

U.S. Remote Patient Monitoring Market Companies

Few of the prominent players operating in the U.S. remote patient monitoring industry include:

• Abbott Laboratories
• Baxter International
• BIOTRONIK SE & Co. KG
• Boston Scientific
• Dexcom
• F. Hoffmann-La Roche Ltd
• GE Healthcare
• Johnson & Johnson
• Koninklijke Philips N.V.
• Medtronic
• OMRON
• Sotera Wireless
• VitalConnect
   
• Dexcom

Dexcom is a leading player in remote patient monitoring for diabetes care, offering advanced continuous glucose monitoring solutions such as the Dexcom G7 CGM system. This device provides real-time glucose readings and trend data to support timely treatment decisions and improve patient outcomes.
 

• Abbott Laboratories 

Abbott Laboratories is a leading player in remote patient monitoring, recognized for its innovations in diabetes care through continuous glucose monitoring technologies. Its FreeStyle Libre 2 system is the only FDA-cleared integrated CGM for adults and children aged 4 years and older, providing up to 14 days of continuous glucose readings with exceptional accuracy. Abbott focuses on user comfort, connectivity, and digital integration, enabling real-time data sharing and proactive management of chronic conditions.
 

• Boston Scientific

Boston Scientific is a leading innovator in cardiac remote patient monitoring, offering solutions such as the HeartLogic Heart Failure Diagnostic system. This advanced platform enables early detection of worsening heart failure by combining multiple physiologic sensors into a single index. It aggregates data such as thoracic impedance, heart sounds, respiration rate, and physical activity into actionable alerts, allowing clinicians to intervene proactively and improve patient outcomes.
 

U.S. Remote Patient Monitoring Industry News:

• In May 2025, Boston Scientific Corporation received FDA approval for LATITUDE 6.0, a software upgrade to its LATITUDE Patient Management system that enhances remote monitoring by offering expanded patient follow-up data history. This upgrade strengthened the company’s digital health portfolio and supports improved clinician efficiency and patient management.
   
• In April 2023, Abbott received U.S. FDA for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system, the world’s smallest, thinnest, and most discreet 5 glucose sensor in diabetes management. Such product approvals strengthened the company’s foothold in the diabetes care market.
   

The U.S. remote patient monitoring market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Cardiac monitoring devices
• Blood pressure monitoring devices
• Neurological monitoring devices
• Respiratory monitoring devices
• Multiparameter monitoring devices
• Blood glucose monitoring devices
• Fetal and neonatal monitoring devices
• Sleep monitoring devices
• Other products         

Market, By Application

• Cardiovascular diseases
• Cancer
• Diabetes
• Neurological disorders
• Infectious diseases
• Respiratory diseases
• Other applications

Market, By End Use

• Home-care settings
• Long-term care
• Other end use